Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHNPB-0005
- Development stage
- Preclinical
- Lead developer
- Daehan Nupharm
- Administration
- Subcutaneous
01
Overview
DHNPB-0005 is a preclinical biologic candidate developed by the South Korean pharmaceutical company Daehan Nupharm. The program is focused on the development of a subcutaneous drug delivery technology, which typically involves a recombinant enzyme (such as hyaluronidase) designed to facilitate the subcutaneous administration of large-molecule therapeutics. By temporarily modifying the extracellular matrix at the injection site, DHNPB-0005 aims to enable the delivery of high-volume biologics that would otherwise require intravenous infusion. This approach is intended to improve patient convenience, reduce administration time, and enhance the overall therapeutic profile of co-administered biologics.
Beyond the preview
Go deeper on DHNPB-0005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHNPB-0005.